Literature DB >> 21938511

Transgenic mice that overexpress human IL-15 in enterocytes recapitulate both B and T cell-mediated pathologic manifestations of celiac disease.

Seiji Yokoyama1, Kazuko Takada, Masatomo Hirasawa, Liyanage P Perera, Takachika Hiroi.   

Abstract

Celiac disease (CD) is a chronic immune-mediated intestinal inflammatory disorder afflicting genetically susceptible individuals triggered by the consumption of dietary cereals with high gluten content. As with many other organ-specific autoimmune diseases, the dominant tissue-destructive inflammation in CD is T cell-mediated. The proinflammatory cytokine IL-15 that is overexpressed in the intestinal epithelium of CD patients has emerged as a pivotal element that orchestrates intestinal inflammation and T cell-mediated autoimmune tissue destruction. Although no animal model exists that recapitulates the full spectrum of CD pathophysiology, we have previously reported that transgenic mice that overexpress human IL-15 in enterocytes (T3(b)-hlL-15 Tg) display many of the T cell-mediated pathologic features seen in CD. Extending these observations, we now report that T3(b)-hlL-15 Tg mice in addition to recapitulating T cell-mediated effects also display autoantibodies including those against tissue transglutaminase 2 and extensive lamina propria plasmacytosis, all of which are characteristic of CD, thereby reflecting the possibility that locally expressed IL-15 drives both T and B cell pathologic effects seen in CD. More importantly, these findings support the validity and utility of T3(b)-hlL-15 Tg mice as a reasonable model to investigate not only tissue-destructive pathologic processes in CD, but also to explore novel therapeutic modalities for the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938511     DOI: 10.1007/s10875-011-9586-7

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

1.  Identification of tissue transglutaminase as the autoantigen of celiac disease.

Authors:  W Dieterich; T Ehnis; M Bauer; P Donner; U Volta; E O Riecken; D Schuppan
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

2.  IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis.

Authors:  Georgia Malamut; Raja El Machhour; Nicolas Montcuquet; Séverine Martin-Lannerée; Isabelle Dusanter-Fourt; Virginie Verkarre; Jean-Jacques Mention; Gabriel Rahmi; Hiroshi Kiyono; Eric A Butz; Nicole Brousse; Christophe Cellier; Nadine Cerf-Bensussan; Bertrand Meresse
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

3.  Systemically derived large intestinal CD4(+) Th2 cells play a central role in STAT6-mediated allergic diarrhea.

Authors:  M N Kweon; M Yamamoto; M Kajiki; I Takahashi; H Kiyono
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

4.  Increased levels of IgA antibodies against desmin in children with coeliac disease.

Authors:  K Teesalu; O Uibo; N Kalkkinen; P Janmey; R Uibo
Journal:  Int Arch Allergy Immunol       Date:  2001-10       Impact factor: 2.749

5.  Small intestinal plasma cells in coeliac disease.

Authors:  B B Scott; A Goodall; P Stephenson; D Jenkins
Journal:  Gut       Date:  1984-01       Impact factor: 23.059

Review 6.  Interleukin 15: its role in inflammation and immunity.

Authors:  L P Perera
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2000       Impact factor: 4.291

7.  A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.

Authors:  Sophie Hüe; Jean-Jacques Mention; Renato C Monteiro; ShaoLing Zhang; Christophe Cellier; Jacques Schmitz; Virginie Verkarre; Nassima Fodil; Seiamak Bahram; Nadine Cerf-Bensussan; Sophie Caillat-Zucman
Journal:  Immunity       Date:  2004-09       Impact factor: 31.745

8.  Jejunal plasma cells and in vitro immunoglobulin production in adult coeliac disease.

Authors:  G M Wood; P D Howdle; L K Trejdosiewicz; M S Losowsky
Journal:  Clin Exp Immunol       Date:  1987-07       Impact factor: 4.330

9.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

10.  Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes.

Authors:  Seiji Yokoyama; Nobumasa Watanabe; Noriko Sato; Pin-Yu Perera; Lyvouch Filkoski; Toshiyuki Tanaka; Masayuki Miyasaka; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-01       Impact factor: 11.205

View more
  11 in total

Review 1.  Latest in vitro and in vivo models of celiac disease.

Authors:  Samantha Stoven; Joseph A Murray; Eric V Marietta
Journal:  Expert Opin Drug Discov       Date:  2013-01-08       Impact factor: 6.098

2.  Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis.

Authors:  Alain P Vicari; Alain M Schoepfer; Bertrand Meresse; Laurence Goffin; Olivier Léger; Soheila Josserand; Nicolas Guégan; Shida Yousefi; Alex Straumann; Nadine Cerf-Bensussan; Hans-Uwe Simon; Yolande Chvatchko
Journal:  MAbs       Date:  2017-06-05       Impact factor: 5.857

Review 3.  Lessons from rodent models in celiac disease.

Authors:  N Korneychuk; B Meresse; N Cerf-Bensussan
Journal:  Mucosal Immunol       Date:  2014-10-29       Impact factor: 7.313

Review 4.  T lymphocytes in the intestinal mucosa: defense and tolerance.

Authors:  Hongdi Ma; Wanyin Tao; Shu Zhu
Journal:  Cell Mol Immunol       Date:  2019-02-20       Impact factor: 11.530

5.  Human monocytes have increased IFN-γ-mediated IL-15 production with age alongside altered IFN-γ receptor signaling.

Authors:  Naeun Lee; Min Sun Shin; Ki Soo Kang; Seung-Ah Yoo; Subhasis Mohanty; Ruth R Montgomery; Albert C Shaw; Insoo Kang
Journal:  Clin Immunol       Date:  2014-03-19       Impact factor: 3.969

6.  Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease.

Authors:  Seiji Yokoyama; Pin-Yu Perera; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  J Clin Immunol       Date:  2012-12-28       Impact factor: 8.317

7.  Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).

Authors:  Seiji Yokoyama; Pin-Yu Perera; Seigo Terawaki; Nobumasa Watanabe; Osamu Kaminuma; Thomas A Waldmann; Takachika Hiroi; Liyanage P Perera
Journal:  J Clin Immunol       Date:  2015-10-09       Impact factor: 8.317

8.  IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection.

Authors:  P Kumar; M S Thakar; W Ouyang; S Malarkannan
Journal:  Mucosal Immunol       Date:  2012-06-27       Impact factor: 7.313

9.  Interleukin-15 modulates adipose tissue by altering mitochondrial mass and activity.

Authors:  Nicole G Barra; Rengasamy Palanivel; Emmanuel Denou; Marianne V Chew; Amy Gillgrass; Tina D Walker; Josh Kong; Carl D Richards; Manel Jordana; Stephen M Collins; Bernardo L Trigatti; Alison C Holloway; Sandeep Raha; Gregory R Steinberg; Ali A Ashkar
Journal:  PLoS One       Date:  2014-12-17       Impact factor: 3.240

Review 10.  Animal models to study gluten sensitivity.

Authors:  Eric V Marietta; Joseph A Murray
Journal:  Semin Immunopathol       Date:  2012-05-11       Impact factor: 11.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.